Minneapolis, MN (PRWEB) February 5, 2010
Arrowhead Publishers and Conferences is pleased to announce the addition of three new speakers to their lineup at the Annual Personalized Medicine Partnerships Conference, set to take place on February 22nd through the 24th in Philadelphia, PA.
New additions include Patrik Kolar, Head of Unit, Genomics and Systems Biology, European Commission, Zing-Jian Lou, Ph.D., Program Director, SBIR (Small Business Innovation Research), National Cancer Institute and Michael Christman, Ph.D., President and CEO, Coriell Institute for Medical Research.
Dr. Kolar will be discussing the ongoing collaborations the European Commission has entered into with the European pharmaceutical industry and life sciences funding agencies around the world, while Dr. Lou will be sharing with the audience details of the SBIR’s new funding priorities for companion diagnostics in cancer therapy and will be outlining current funding opportunities. Dr. Christman will present details relating to Coriell’s new Personalized Medicine Collaborative, which is a groundbreaking new study into the real world utility of using personalized genome information in the clinic. The goal of the project is to determine best practices in the implementation of personalized medicine.
Current headlines coming out of Washington suggest that personalized medicine has taken on a level of importance heretofore unseen. Personalized medicine is defined as the application of genomic and molecular data to better target the delivery of health care, facilitate the discovery and clinical testing of new products, and help determine a person's predisposition to a particular disease or condition.
This year’s conference will focus on the importance of partnerships in advancing the field of personalized medicine on a global scale. Key issues to be discussed at this conference include:
- What pharmaceutical and diagnostic companies are looking for in a partner
- Partnering challenges that arise within the realm of contractual negotiations, IP protection, regulatory affairs and commercialization
- Benefits of partnerships, including more effective, efficient and safer clinical trials
- How and when to start a relationship, ie. discovery, clinical, post-commercialization?
- The risks of partnering
CLICK HERE to view the agenda
Organizations attending this year include Abbott Molecular, Biocrates Life Sciences, Biodesix, Eli Lilly, Gen-Probe, Genomic Health, Life Technologies, Medimmune, Myriad Genetics, Oncomethylome, OSI Pharmaceuticals, Roche Molecular Diagnostics, sanofi-aventis, FDA, National Human Genome Institute, AstraZeneca, Merck, National Cancer Institute, European Commission, bioMerieux, Tethys Bioscience, DNA Direct, Price Waterhouse Coopers, Diaceutics, Scientia Advisors, Medco, GE Healthcare, AlliedPath, 20/20 GeneSystems and many others.
Featured speakers at this year’s conference include:
- Christopher Austin, MD, Director, NIH Chemical Genomics Center, National Human Genome Institute
- Stafford O'Kelly, President, Abbott Molecular
- Elizabeth Mansfield, Ph.D., Sr. Director, Genomics and Personalized Medicine, FDA Office of the Commissioner
- Michael F. Christman, Ph.D., President and CEO, Coriell Institute for Medical Research
- Cecilia Schott, PharmD., MBA, Business Development Director, Personalized Healthcare, Strategic Planning and Business Development, AstraZeneca
- Patrik Kolar, Ph.D., Head of Unit, European Commission CORDIS , Directorate-General for Research, Genomics and Systems Biology
- Linda Egger, Ph.D., Senior Director, Scientific Liaison , External Scientific Affairs - Oncology Licensing, Merck & Co.
- Xing-Jian Lou, Ph.D, Program Director, SBIR Development Center, National Cancer Institute
Please CLICK HERE to see the full list of speakers